Separate terms with OR to return results that match either term.
 
Clear All

9,635 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70771-1350-04 70771-1350 methylprednisolone methylprednisolone 16.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1350-05 70771-1350 methylprednisolone methylprednisolone 16.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1350-07 70771-1350 methylprednisolone methylprednisolone 16.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1351-01 70771-1351 methylprednisolone methylprednisolone 32.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1351-04 70771-1351 methylprednisolone methylprednisolone 32.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1351-05 70771-1351 methylprednisolone methylprednisolone 32.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1351-08 70771-1351 methylprednisolone methylprednisolone 32.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2018 In Use
70771-1374-03 70771-1374 Exemestane Exemestane 25.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral Oct. 8, 2018 In Use
70771-1394-05 70771-1394 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 21, 2021 In Use
70771-1394-09 70771-1394 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 21, 2021 In Use
70771-1395-03 70771-1395 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 21, 2021 In Use
70771-1395-05 70771-1395 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 21, 2021 In Use
70771-1395-08 70771-1395 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 21, 2021 In Use
70771-1395-09 70771-1395 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 21, 2021 In Use
70771-1521-03 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1521-07 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1521-09 70771-1521 Erlotinib Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1522-03 70771-1522 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1522-07 70771-1522 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1522-09 70771-1522 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-03 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-07 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-09 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1626-08 70771-1626 Fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 14, 2021 In Use
70771-1677-01 70771-1677 LENALIDOMIDE LENALIDOMIDE 5.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Sept. 12, 2022 In Use

Found 9,635 results in 21 millisecondsExport these results